Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats

被引:17
作者
Kim, EJ
Suh, OK
Lee, MG
机构
[1] Seoul Natl Univ, Coll Pharm, Kwanak Gu, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Kwanak Gu, Seoul 151742, South Korea
关键词
theophylline; 1,3-DMU; pharmacokinetics; mutant Nagase analbuminemic rats; CYP1A2;
D O I
10.1016/S0024-3205(02)02373-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It was obtained from our laboratories that the expression of hepatic microsomal cytochrome P450 (CYP) 1A2 increased approximately 3.5 times in mutant Nagase analbuminemic rats (NARs, an animal model for human familial analbuminemia), and theophylline was reported to be metabolized to 1,3-dimethyluric acid (1,3-DW) and 1-methylxanthine (which was further metabolized to 1-methyluric acid, 1-MU, via xanthine oxidase) via CYP1A2 in rats. Hence, the pharmacokinetic parameters of theophylline, 1,3-DMU and 1-MU were compared after intravenous administration of aminophylline, 5 mg/kg as theophylline, to control Sprague-Dawley rats and NARs. In NARs, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of theophylline was significantly smaller (1040 versus 1750 mug min/ml) than that in control rats and this could be due to significantly faster renal clearance (CLR, 1.39 versus 0.571 ml/min/kg, due to inhibition of renal reabsorption of unchanged theophylline) and nonrenal clearance (CLNR, 3.36 versus 2.25 ml/min/kg, due to 3.5-fold increase in CYP1A2) than those in control rats. Based on in vitro hepatic microsomal studies, the intrinsic 1,3-DMU formation clearance was significantly faster in NARs than that in control rats (267 versus 180 x 10(-6) ml/min). After intravenous administration of 1,3-DMU, the renal secretion of 1,3-DMU was inhibited in NARs. Inhibition of renal secretion or reabsorption of various compounds in NARs was also discussed. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1231 / 1245
页数:15
相关论文
共 37 条
[1]  
BIRKET DJ, 1984, CLIN EXP PHARM PHYSL, V8, P48
[2]   NEW CALCULATION METHOD OF MEAN TOTAL-BODY CLEARANCE OF DRUGS AND ITS APPLICATION TO DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (01) :90-91
[3]   NEW CALCULATION METHOD FOR MEAN APPARENT DRUG VOLUME OF DISTRIBUTION AND APPLICATION TO RATIONAL DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1067-1069
[4]   CRITICAL EVALUATION OF THE POTENTIAL ERROR IN PHARMACOKINETIC STUDIES OF USING THE LINEAR TRAPEZOIDAL RULE METHOD FOR THE CALCULATION OF THE AREA UNDER THE PLASMA LEVEL TIME CURVE [J].
CHIOU, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (06) :539-546
[5]  
Chung SY, 1997, RES COMMUN MOL PATH, V98, P255
[6]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[7]   PHARMACOKINETICS OF DIAZEPAM FOLLOWING MULTIPLE-DOSE ORAL-ADMINISTRATION TO HEALTHY HUMAN SUBJECTS [J].
EATMAN, FB ;
COLBURN, WA ;
BOXENBAUM, HG ;
POSMANTER, HN ;
WEINFELD, RE ;
RONFELD, R ;
WEISSMAN, L ;
MOORE, JD ;
GIBALDI, M ;
KAPLAN, SA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (05) :481-494
[8]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[9]  
GREEN TP, 1981, J PHARMACOL EXP THER, V218, P122
[10]   DISPOSITION OF PHENYTOIN IN ANALBUMINEMIC RATS [J].
HIRATE, J ;
HORIKOSHI, I ;
NAGASE, S .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (09) :773-783